http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-036320-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c76ecadad74a1a35270b3e3a34d60f37 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-382 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D453-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-227 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-227 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-536 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-538 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4523 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D453-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-30 |
| filingDate | 2000-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2004-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-036320-A1 |
| titleOfInvention | SUBSTITUTED BENZOLACTAMA COMPOUNDS, THEIR USE IN THE MANUFACTURE OF MEDICINES AND THE COMPOSITIONS OF THE SAME |
| abstract | Claim 1: A method of treating a disorder or condition selected from dysthymia, major depressive disorder, pediatric depression, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, phobias such as social phobia and agoraphobia; post-traumatic stress disorder, borderline personality disorder, acute pain, chronic, migraine pain, angiogenesis, sunburn, urinary incontinence, inflammatory disorders such as rheumatoid arthritis, osteoarthritis, psoriasis and asthma; emesis, including acute, delayed and anticipated emesis in which the state or the emetic agent is chemotherapy, radiation, surgery, movement, migraine or any other state or emetic agent; disorders caused by Helicobacter pylory, cardiovascular disorders, ophthalmic disorders, urinary tract inflammation, psychosis, schizophrenia, behavior disorder, disruptive behavior disorder, bipolar disorder, movement disorders such as Tourette's syndrome, akinesia-stiffness syndrome, movement disorders associated with Parkinson's disease, tardive dyskinesia and other dyskinesias, cognitive disorders such as dementia (including age-related dementia and senile dementia of the Alzheimer type) and memory disorders; eating disorders such as anorexia nervosa and bulimia nervosa, attention deficit hyperactivity disorder, chronic fatigue syndrome, premature ejaculation, premenstrual syndrome, premenstrual dysphoric disorder, chemical dependencies and addictions, stress-related somatic disorders, neuralgia , peripheral neuropathy, gastroesophageal reflux disease, reflex sympathetic dystrophy, such as shoulder / hand syndrome; hypersensitivity disorders such as hypersensitivity to poison ivy; fibromyalgia, angina, Reynaud's disease, rheumatic diseases such as fibrositis; eczema, rhinitis, allergies, post-herpetic neuralgia, cystitis, inflammatory bowel disease, irritable bowel syndrome, colitis, fibrous and collagen disorders such as scleroderma and eosinophilic fascioliasis; blood circulation disorders due to vasodilation, and disorders related to immune induction or suppression such as systemic lupus erythematosus, in a mammal, including a human being, comprising administering to the mammal in need of such treatment a quantity of a compound of formula chemistry (1), in which W is methylene, ethylene, propylene, vinyl, -CH2-O-, -O-CH2, -CH2-S- or -S-CH2-; R1, R2 and R3 are independently hydrogen, C1-3 alkyl, C1-3 alkoxy-C1-3 alkyl or halo-C1-3 alkyl, with the proviso that when W is methylene, neither R2 nor R3 is hydrogen; or one of R2 or R3 can be hydroxy; X is halo, C1-3 alkoxy, C1-3 alkyl, halo C1-3 alkoxy or C1-3 alkenyl; Y is -NH or -O-; Q is oxygen or sulfur and has a double bond with the carbon to which it is attached, or Q is CH3 and has a single bond with the carbon to which it is attached; and T is (2S, 3S) -2-diphenylmethylquinuclidin-3-yl, (2S, 3S) -2-diphenylmethyl-1-azanorbornan-3-yl; or (2S, 3S) -2-phenylpiperidin-3-yl, the phenyl group of said (2S, 3S) -2-phenylpiperidin-3-yl being optionally substituted with one or more substituents, preferably 0 to 3 substituents, selected independently between halo, C1-6 alkyl optionally substituted with 1 to 7 fluorine atoms, C1-6 alkoxy optionally substituted with 1 to 7 fluorine atoms, amino, cyano, nitro, C1-6-amino alkyl and di [alkyl C1-6] amino; and the dashed line represents an optional double bond; with the proviso that R1 cannot be (C1-3 alkoxy) -CH2- or halo-CH2-; or of a pharmaceutically acceptable salt thereof, which is effective in the treatment of such disorder or condition. Claim 6: A pharmaceutical composition for the treatment of a disorder or condition selected from dysthymia, major depressive disorders, pediatric depression, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, phobias such as social phobia and agoraphobia; post-traumatic stress disorder and borderline personality disorder in a mammal, comprising an amount of a compound of formula (1), or a pharmaceutically acceptable salt thereof, which is effective in treating such disorder or condition, and a pharmaceutically acceptable vehicle. |
| priorityDate | 1999-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 92.